Johnson & Johnson Announces New Pharmaceutical and MedTech Business Segment Branding

September 14, 2023—Johnson & Johnson announced that it is uniting both its medtech and pharmaceutical segments under the Johnson & Johnson brand name.

According to the company, the announcement marks the beginning of a new era for Johnson & Johnson, which was founded in 1886.

Janssen, the company’s pharmaceutical segment—including Xarelto (rivaroxaban) for antithrombotic therapy—will be named Johnson & Johnson Innovative Medicine. The segment addresses complex diseases to develop potential medicines in the areas of oncology, immunology, neuroscience, cardiovascular, pulmonary hypertension, and retina.

The medical technology segment, which will continue to be named Johnson & Johnson MedTech, develops innovations at the intersection of biology and technology for surgery, orthopedics, vision, and interventional solutions.

The MedTech segment includes the Abiomed and Biosense Webster electrophysiology businesses. In December 2022, Johnson & Johnson announced the completion of its acquisition of Abiomed, whose Impella heart pumps have earned FDA approvals for treatment of patients with severe coronary artery disease requiring high-risk percutaneous coronary intervention; acute myocardial infarction; cardiogenic shock; and right heart failure.

The company stated it seeks to leverage its expertise in medicine and medical technology to prevent, treat, and cure complex diseases and introduce solutions that are smarter, less invasive, and more personalized.

The press release noted that the new Johnson & Johnson brand identity builds on the company’s legacy, while also modernizing key elements to showcase healthcare innovation. This initiative includes a newly styled, modernized logo and art direction to reflect the company's updated brand.

“Our exclusive focus on Innovative Medicine and MedTech solutions enables us to innovate across the full spectrum of healthcare in ways no other company can,” commented Joaquin Duato, Chairman of the Board and Chief Executive Officer, in the company's press release. “Uniting our diverse businesses under an updated Johnson & Johnson brand reflects our unique ability to reimagine healthcare through transformative innovation, while staying true to ‘Our Credo’ values and the level of care that patients and doctors expect of us.”